Concor Plus 5 mg / 12.5 mg is a fixed-dose combination oral prescription medication formulated for the treatment of essential hypertension (high blood pressure) in adult patients whose condition requires multi-agent therapy or is insufficiently managed with single-agent beta-blocker or diuretic therapy alone.
By combining two distinct active pharmacological agents—Bisoprolol fumarate (a cardioselective beta-1 receptor blocker) and Hydrochlorothiazide (a thiazide diuretic)—Concor Plus concurrently decreases cardiac output and lowers total peripheral fluid volume to achieve consistent, effective blood pressure reduction.
Active Ingredients & Dual-Action Mechanism
Concor Plus incorporates two complementary active substances that address blood pressure regulation through independent physiological mechanisms:
Bisoprolol Fumarate (5 mg per tablet): A highly selective beta-1 adrenoreceptor antagonist. It selectively binds to cardioselective beta-1 receptors in the heart, reducing heart rate, decreasing myocardial contractility, and lowering cardiac workload. Additionally, bisoprolol suppresses the release of renin from the kidneys, inhibiting the renin-angiotensin-aldosterone system (RAAS).
Hydrochlorothiazide (12.5 mg per tablet): A thiazide diuretic that acts on the distal renal tubules in the kidneys. It inhibits active sodium and chloride ion reabsorption, increasing urinary excretion of sodium, chloride, and water, thereby reducing intravascular circulating blood volume and venous return.
Dual Mechanism of Action
Hemodynamic Balance: Bisoprolol reduces the force and frequency of heart contractions, preventing surge elevations in arterial pressure.
Volumetric Reduction: Hydrochlorothiazide removes excess fluid and salts from the vascular space, lowering total blood volume and wall tension in arterial blood vessels.
Therapeutic Synergy: Combining a low-dose beta-blocker with a low-dose thiazide diuretic enhances overall antihypertensive efficacy compared to higher doses of either agent administered alone, while helping minimize dose-dependent side effects.
Key Medical Indications & Clinical Benefits
Targeted Blood Pressure Management: Indicated for adult patients requiring combination therapy to reach clinical blood pressure goals.
Cardiovascular Protection: Lowering systemic arterial pressure significantly decreases the long-term risk of cardiovascular events, including cardiovascular mortality, strokes, and myocardial infarctions.
Balanced Dosing Profile: The 5 mg / 12.5 mg combination allows for sustained 24-hour blood pressure control with convenient once-daily dosing.
Usage Instructions & Dosage Protocol
Important: Concor Plus is a prescription-only medicine. Treatment must be initiated, titrated, and monitored under the supervision of a licensed healthcare practitioner.
Standard Dosage: The usual therapeutic dose is one tablet (5 mg / 12.5 mg) once daily.
Administration: Tablets should be taken in the morning, swallowed whole with liquid. They may be taken with or without food, but should not be chewed or crushed.
Treatment Duration: Essential hypertension typically requires long-term continuous therapy. Discontinuation of treatment should be gradual under medical guidance to prevent rebound hypertension.
Missed Dose: If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Never take two doses simultaneously to compensate for a missed tablet.
Safety Precautions, Warnings & Contraindications
Absolute Contraindications
Acute or Decompensated Heart Failure: Not indicated during acute heart failure episodes or unstable cardiac decompensation requiring intravenous inotropic therapy.
Severe Bradycardia & Heart Block: Contraindicated in patients with marked sinus bradycardia (resting heart rate below 50 beats per minute), second- or third-degree AV block (without a pacemaker), or sick sinus syndrome.
Severe Asthma & Obstructive Airway Disease: Severe chronic obstructive pulmonary disease (COPD) or active bronchial asthma.
Pregnancy & Lactation: Contraindicated during pregnancy due to potential adverse effects on fetal renal function, placental perfusion, and fetal development.
Severe Renal or Hepatic Impairment: Anuria, severe kidney dysfunction (creatinine clearance less than 30 mL/min), or severe liver impairment.
Electrolyte Disturbances: Refractory hypokalemia, severe hyponatremia, hypercalcemia, or symptomatic hyperuricemia (gout).
General Warnings & Precautions
Abrupt Discontinuation: Beta-blocker therapy must not be stopped suddenly, especially in patients with ischemic heart disease, as this can precipitate angina pectoris or myocardial infarction. Dose reduction must be gradual over 1 to 2 weeks.
Electrolyte & Metabolic Monitoring: Hydrochlorothiazide can affect serum potassium, sodium, glucose, and uric acid levels. Periodic laboratory blood tests are advised.
Diabetes Mellitus: Bisoprolol can mask symptoms of acute hypoglycemia (particularly tachycardia). Regular blood glucose monitoring is recommended for diabetic patients.
Drug Interactions: Concomitant use with other antihypertensives, calcium channel blockers (e.g., verapamil, diltiazem), antiarrhythmics, NSAIDs, or lithium requires careful clinical monitoring.
Product Specifications & Storage
Formulation: Film-coated tablets.
Pack Size: 20 film-coated tablets.
Storage Conditions: Store below 30°C in the original blister pack to protect tablets from moisture and direct light. Keep out of reach and sight of children.
Medication
